University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

University of Tübingen, a leading member of Cyber Valley, Europe's largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

The partners will define cutting-edge research topics at the intersection of health and applications of AI, which will be selected by a joint steering committee. First fellowships have been published here and interested post-doctoral candidates are invited to submit their applications.

The partnership is founded in Boehringer Ingelheim’s and the University of Tübingen's joint vision to harness the power of AI and data science to improve human and animal health. The aim is to transform patient’s lives through the discovery of new medical breakthroughs, by accelerating timelines, improving scientific and clinical success and further elevating patient centricity. Application areas will reach across the whole biopharmaceutical value chain, from research and development via production and supply chain management to marketing and sales.

Jan Nygaard Jensen, Global Head of Computational Biology and Digital Sciences at Boehringer Ingelheim said, "The partnership with University of Tübingen, will boost our AI and data science research and give us the opportunity to develop and recruit the next generation of AI and data scientists. These talents will be key in achieving our goal to accelerate development of novel treatments and transform the lives of millions of humans and animals."

"Only if we leverage the potential of new digital technologies will we achieve our goal of bringing the future of healthcare to people around the globe. This is why digital innovation transcends all areas at Boehringer Ingelheim under one consistent strategy to maximize this opportunity. We are very excited to work with the fellows to extend our leadership in the development of next-gen AI and data science solutions," added Brigitte Fuhr, Head of Central Data Science at Boehringer Ingelheim.

"This collaboration with a research-driven biopharmaceutical company like Boehringer-Ingelheim is a partnership of mutual interest and could pave the way for further initiatives," says Professor Dr. Peter Grathwohl, Vice-president for Research and Innovation at the University of Tübingen. "The University establishes yet another interface between basic research and practical application here. It also sharpens its profile in a research area of increasing importance: the use of AI in medicine and the life sciences."

"Particularly in the combination of AI with relevant healthcare and pharmaceutical data, there is great potential to noticeably improve the wellbeing of many people," says Nico Pfeifer, professor of Methods in Medical Informatics at the University of Tübingen and project director. "Methods research is able to identify problems in the healthcare sector which require new AI approaches and can develop tailored solutions for them."

Fellows will do their research onsite at University of Tübingen. They will benefit from the University's extensive expertise, rapid growth in AI and data science and highly reputed medical research. In addition, they will have the opportunity to work closely with scientists, domain experts, and executives from Boehringer Ingelheim globally and locally. Furthermore, it is planned that fellows will be invited to participate in visits at the company's sites, networking events and annual symposia.

The University of Tübingen is committed to the transfer of innovations and research results to application and to maintaining a continuous exchange with industry and society. In the field of AI, it is a founding member of the Cyber Valley research network and conducts applied basic research in a wide range of collaborations. It focuses on applications for science itself - for example in the Cluster of Excellence "Machine Learning: New Perspectives for Science" -, life sciences and medicine, but also ethical aspects.

Boehringer Ingelheim's digital strategy aims to establish a leading data science ecosystem by collaborating with top-notch academic research institutions in the field, by nourishing and developing future talent and by partnering with data initiatives globally to build a comprehensive global data base of genomic and patient data. The company is collaborating with innovative digital startups across the whole value chain and is investing in early digital entrepreneurs via the company's venture fund BIVF.

With the newly established collaboration with the University of Tübingen Boehringer Ingelheim continues to foster AI and data science partnerships in multiple innovation spots in Europe, the USA and Asia. Last year a similar fellowship program was established with Yale University together with Boehringer Ingelheim's Ridgefield R&D site.

About The University of Tübingen

The University of Tübingen is one of eleven universities judged excellent under the German government's Excellence Initiative, and ranks well in international comparisons. Tübingen is one of the world’s foremost locations for neuroscientific research. Along with translational immunology and cancer research, microbiology and infection research, and molecular plant biology, it makes Tübingen a cutting-edge center of research in the Life Sciences. Further areas of core research are in Machine Learning, Geoscience and Environmental Science; Archaeology and Anthropology; Language and Cognition; and Education and the Media. More than 27,000 students from Germany and around the world are currently enrolled at the University of Tübingen, enjoying a broad spectrum of some 200 different study programs.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Most Popular Now

Should AI Chatbots Replace Your Therapis…

The new study exposes the dangerous flaws in using artificial intelligence (AI) chatbots for mental health support. For the first time, the researchers evaluated these AI systems against clinical standards...

AI could Help Pathologists Match Cancer …

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how...

AI Detects Early Signs of Osteoporosis f…

Investigators have developed an artificial intelligence-assisted diagnostic system that can estimate bone mineral density in both the lumbar spine and the femur of the upper leg, based on X-ray images...

AI Tool Detects Surgical Site Infections…

A team of Mayo Clinic researchers has developed an artificial intelligence (AI) system that can detect surgical site infections (SSIs) with high accuracy from patient-submitted postoperative wound photos, potentially transforming...

AI Sharpens Pathologists' Interpret…

Pathologists' examinations of tissue samples from skin cancer tumours improved when they were assisted by an AI tool. The assessments became more consistent and patients' prognoses were described more accurately...

Meet Your Digital Twin

Before an important meeting or when a big decision needs to be made, we often mentally run through various scenarios before settling on the best course of action. But when...

NHS National Rehabilitation Centre to De…

The new NHS National Rehabilitation Centre will deploy technology to help patients to maintain their independence as they recover from life-changing injuries and illnesses and regain quality of life. Airwave Healthcare...

AI Finds Hundreds of Potential Antibioti…

Snake, scorpion, and spider venom are most frequently associated with poisonous bites, but with the help of artificial intelligence, they might be able to help fight antibiotic resistance, which contributes...

AI Tool Accurately Detects Tumor Locatio…

An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a study published...

AI can Accelerate Search for More Effect…

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in...

AI Accurately Classifies Pancreatic Cyst…

Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance Imaging...

Free AI Tools can Help Doctors Read Medi…

A new study from the University of Colorado Anschutz Medical Campus shows that free, open-source artificial intelligence (AI) tools can help doctors report medical scans just as well as more...